Skip to content
Business
Prognosis

New Covid Boosters Aren’t Better Than Old Ones, Study Finds

  • Results show the new shots perform similarly to past ones
  • Moderna, Pfizer boosters aim to protect against new variants
Bloomberg business news
Brace for a Covid Surge, US Surgeon General Murthy Warns
Updated on

Bivalent booster shots from Moderna Inc. and Pfizer Inc. failed to raise levels of protective proteins called neutralizing antibodies against the dominant omicron strains any more than four doses of the original Covid vaccine, according to an early independent study on a small group of people.

Researchers at Columbia University and the University of Michigan compared levels of neutralizing antibodies in blood samples from 21 people who got a fourth shot of the Moderna or Pfizer-BioNTech SE bivalent boosters against antibody levels in 19 people who got four shots of the original vaccines.